# US 11,298,396 B2 · Agent for inhibiting or reducing light sensitivity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,298,396 B2
- Document ID: US11298396B2
- Status: Granted
- Kind: B2
- Application number: 16/494,464
- Filed: 2018-03-16
- Published: 2020-01-16
- Granted: 2022-04-12
- Earliest claimed: 2017-03-17
- Assignees: Osaka University
- Applicants: Osaka University
- Inventors: Takahisa Furukawa
- Web page: https://patentgrep.com/patent/US11298396B2

## CPC

- A61K 38/005: {Enzyme inhibitors (protease inhibitors A61K38/55)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/502: {for testing non-proliferative effects}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed is an agent for inhibiting or reducing light sensitivity comprising a substance that inhibits or reduces ubiquitination, for example, an agent for inhibiting or reducing light sensitivity capable of protecting a retina, reducing retinal degeneration, reducing aging of a retina and/or reducing hyperesthesia. The present invention is suitable for use in amelioration or prevention of a symptom associated with light reception, such as age-related macular degeneration, retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease, cone-rod dystrophy, diabetic retinopathy, macular edema, retinal ischemia, photosensitive seizure, photosensitive epilepsy, psychiatric disorders, photic maculopathy, asthenopia, retinal dysfunction, sleep disorders, migraine and light-induced damage.

## Claims

### Claim 1

A method for inhibiting or reducing light sensitivity of a
retina, the method comprising administering to an animal a substance that inhibits or reduces Kelch-like 18 (Klhl18), wherein the substance is MLN4924 or the C terminal fragment of Klhl18, wherein the C-terminal fragment is the C-terminal 298 residues of Klhl18.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method is provided to an animal in need of protection of a retina, inhibition of retinal degeneration and/or reduction in hyperesthesia.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the method is provided to an animal in need of an amelioration or prevention of a symptom associated with light reception, wherein the symptom associated with light reception is at least one selected from the group consisting of age-related macular degeneration, retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease, cone-rod dystrophy and light-induced damage.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the Klhl18 is a protein consisting of the amino acid sequence of SEQ ID NO: 3 or 12.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the substance that inhibits or reduces Klhl18 is a substance that inhibits or reduces the expression and/or activity of Klhl18, or a substance that inhibits the activity of a protein component of a Klhl18 complex.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the substance is administered in the form of an injection or an eye drop.